| Literature DB >> 23559278 |
Andrew S Bell1, Joseph Bradley, Jeremy R Everett, Michelle Knight, Jens Loesel, John Mathias, David McLoughlin, James Mills, Robert E Sharp, Christine Williams, Terence P Wood.
Abstract
The screening files of many large companies, including Pfizer, have grown considerably due to internal chemistry efforts, company mergers and acquisitions, external contracted synthesis, or compound purchase schemes. In order to screen the targets of interest in a cost-effective fashion, we devised an easy-to-assemble, plate-based diversity subset (PBDS) that represents almost the entire computed chemical space of the screening file whilst comprising only a fraction of the plates in the collection. In order to create this file, we developed new design principles for the quality assessment of screening plates: the Rule of 40 (Ro40) and a plate selection process that insured excellent coverage of both library chemistry and legacy chemistry space. This paper describes the rationale, design, construction, and performance of the PBDS, that has evolved into the standard paradigm for singleton (one compound per well) high-throughput screening in Pfizer since its introduction in 2006.Mesh:
Substances:
Year: 2013 PMID: 23559278 DOI: 10.1007/s11030-013-9438-x
Source DB: PubMed Journal: Mol Divers ISSN: 1381-1991 Impact factor: 2.943